KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Common Equity (2016 - 2025)

Historic Common Equity for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $7.9 billion.

  • Teva Pharmaceutical Industries' Common Equity rose 4710.04% to $7.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.9 billion, marking a year-over-year increase of 4710.04%. This contributed to the annual value of $7.9 billion for FY2025, which is 4710.04% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Common Equity is $7.9 billion, which was up 4710.04% from $7.3 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Common Equity's 5-year high stood at $11.5 billion during Q3 2021, with a 5-year trough of $5.4 billion in Q4 2024.
  • Its 5-year average for Common Equity is $8.4 billion, with a median of $8.0 billion in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 3379.28% in 2024, then surged by 4710.04% in 2025.
  • Teva Pharmaceutical Industries' Common Equity (Quarter) stood at $11.2 billion in 2021, then decreased by 23.53% to $8.6 billion in 2022, then fell by 5.49% to $8.1 billion in 2023, then tumbled by 33.79% to $5.4 billion in 2024, then skyrocketed by 47.1% to $7.9 billion in 2025.
  • Its last three reported values are $7.9 billion in Q4 2025, $7.3 billion for Q3 2025, and $6.8 billion during Q2 2025.